Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Stay away from companies that roll over the debt e.g. Bear Stearns
When investing in financial institutions, Buffett shies from those who are bigger borrowers of short term than long term debt.
His favorite Wells Fargo has 57 cents short term debt for every dollar of long term.
Aggressive banks (like Bank of America) has $2.09 short term for every dollar long term
Weleader Biomedical Co Total Current Liabilities Related Terms
Weleader Biomedical Co Total Current Liabilities Historical Data
* Premium members only.
The historical data trend for Weleader Biomedical Co's Total Current Liabilities can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Weleader Biomedical Co Total Current Liabilities Chart
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
The increase of Total Current Liabilities of a company is not necessarily a bad thing. This may conserve the company's cash and contribute positively to cash flow.
Total Current Liabilities is linked to Total Current Assets through the Current Ratio and Working Capital. The Current Ratio is equal to dividing total current assets by total current liabilities. It is frequently used as an indicator of a company's liquidity, its ability to meet short-term obligations. Net working capital is calculated as Total Current Assets minus Total Current Liabilities.
What does a Total Current Liabilities of NT$449 Mil mean?
Weleader Biomedical Co (ROCO:7713) has a Total Current Liabilities of NT$449 Mil as of Jun. 2026. The total amount of liabilities with maturity less than one year as recorded on a company's balance sheet. View historical data for Weleader Biomedical Co and its competitors.
Is Weleader Biomedical Co's Total Current Liabilities too high?
Weleader Biomedical Co's current Total Current Liabilities is NT$449 Mil. Overall, Weleader Biomedical Co has a GF Score™ of 66/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Weleader Biomedical Co's Total Current Liabilities compare to ABT and SYK?
Weleader Biomedical Co's Total Current Liabilities of NT$449 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Current Liabilities for a Medical Devices & Instruments company?
A good Total Current Liabilities depends on the Medical Devices & Instruments industry context. However, Total Current Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Current Liabilities mean?
A high Total Current Liabilities can signal that a stock is expensive relative to its fundamentals. The total amount of liabilities with maturity less than one year as recorded on a company's balance sheet. View historical data for Weleader Biomedical Co and its competitors. Weleader Biomedical Co's current Total Current Liabilities is NT$449 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Weleader Biomedical Co stock overvalued right now?
Based on GuruFocus' analysis, Weleader Biomedical Co (ROCO:7713) is currently considered Fairly Valued. The stock's GF Value™ is NT$74.61, compared to a current price of NT$71.10 — trading 4.7% below its estimated fair value. The current Total Current Liabilities is NT$449 Mil. Weleader Biomedical Co's overall GF Score™ is 66/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Current Liabilities calculated?
Total Current Liabilities is calculated from a company's financial statements. For Weleader Biomedical Co (ROCO:7713), the current Total Current Liabilities is NT$449 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Weleader Biomedical Co (ROCO:7713) Overvalued in 2026?
Based on GuruFocus' analysis, Weleader Biomedical Co stock appears to be undervalued.
The current stock price of NT$71.10 is trading 4.7% below its estimated GF Value™ of NT$74.61.
GuruFocus considers Weleader Biomedical Co to be Fairly Valued.
Key valuation signals for ROCO:7713:
Total Current Liabilities: NT$449 Mil
GF Value™: NT$74.61 vs. price of NT$71.10 (4.7% below fair value)
No single metric tells the full story. See the ROCO:7713 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Weleader Biomedical Co Ltd is mainly engages in the sales of medical testing reagents and medical devices; and the leasing of testing instruments. The reportable segments of the Group are: The Company, which includes sale of testing reagents, and provision of testing instruments and services; and Health Leader, which includes sale of dietary supplements and testing reagents, and provision of information and professional services. It derives majority revenue from the Company segment. Geographically, the company operates and generates revenue from Taiwan.
66GF Score
Get the complete analysis for ROCO:7713
Total Current Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:7713 has been successfully added to your 
